Findings from CAS Center for Excellence in Nanoscience Broaden Understanding of Cancer (Inter-crosslinking Peptide Augments 4-1bb Receptor Clustering for Cancer Immunotherapy).
In: Immunotherapy Weekly, 2023-12-26, S. 323-323
serialPeriodical
Zugriff:
Researchers from the CAS Center for Excellence in Nanoscience in Beijing, China have made advancements in cancer immunotherapy by developing a self-assembled peptide ligand that enhances the clustering of the 4-1BB receptor on T cells. The peptide ligand, which has a unique structure, increases the assembly rate, stabilizes the ligand-receptor complex, and triggers the release of proinflammatory cytokines. In a murine tumor model, the ligand also showed potential in supplementing anti-PD-1 therapy. This research provides insights into the regulation of receptor clustering and its potential applications in cancer treatment. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Findings from CAS Center for Excellence in Nanoscience Broaden Understanding of Cancer (Inter-crosslinking Peptide Augments 4-1bb Receptor Clustering for Cancer Immunotherapy).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-12-26, S. 323-323 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|